<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344927</url>
  </required_header>
  <id_info>
    <org_study_id>CRC 340</org_study_id>
    <nct_id>NCT02344927</nct_id>
  </id_info>
  <brief_title>CRT Hydration in the Last Days of Life (Feasibility Study)</brief_title>
  <official_title>A Cluster Randomised Trial of Alternative Forms of Hydration in Cancer Patients in the Last Days of Life (Feasibility Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Surrey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Surrey County Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Christie NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leckhampton Hall Hospice (Cheltenham)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pilgrims Hospices (Kent)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St Clare Hospice (Hastingwood)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New Cross Hospital, Wolverhampton</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St Giles Hospice, Lichfield</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St Mary;s Hospice, Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Velindre NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St Richards Hospice, Worcester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St Catherines Hospice, Crawley</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St Margaret Hospice,Somerset</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Surrey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is unclear whether the use of fluids given by a &quot;drip&quot; is beneficial to cancer patients in&#xD;
      the last days of life, and as a result many individuals do not receive such treatment&#xD;
      (although they do receive fluids by mouth, and regular mouth care). The researchers want to&#xD;
      undertake a large study (&quot;main study&quot;) to determine the benefits of fluids given by a drip,&#xD;
      but first need to undertake a small study (&quot;feasibility study&quot;) to ensure that the main study&#xD;
      can be done.&#xD;
&#xD;
      The feasibility study will be done in twelve units (hospitals, hospices) in England &amp; Wales;&#xD;
      each unit will be allocated a treatment at random, and all patients in the unit will receive&#xD;
      that treatment (if appropriate). Standard treatment A consists of drinking fluids (if&#xD;
      possible), regular mouth care, and treatment of any symptoms; standard treatment B consists&#xD;
      of drinking fluids (if possible) , regular mouth care, fluids by a drip, and treatment of any&#xD;
      symptoms.&#xD;
&#xD;
      Patients will be assessed on a four hourly basis, and any uncontrolled symptoms will be&#xD;
      recorded. The main symptom of interest is agitation (&quot;delirium&quot;), which has multiple causes,&#xD;
      including dehydration and kidney failure. Uncontrolled symptoms will be appropriately&#xD;
      treated, e.g. patients with pain will be given painkillers. Equally, problems relating to the&#xD;
      fluids given by a drip will also be recorded. Involvement in the study will not interfere&#xD;
      with the patient's general care, and there will be no additional blood or other tests.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      The provision of clinically-assisted hydration (CAH) at the end-of-life is one of the most&#xD;
      contentious issues in medicine, and indeed within the general population. The reasons for&#xD;
      contention include:&#xD;
&#xD;
        -  the lack of evidence for / against CAH;&#xD;
&#xD;
        -  the disparate opinions of healthcare professionals about CAH;&#xD;
&#xD;
        -  the generally positive opinions of patients and their carers about CAH (and the&#xD;
           generally negative opinions about withholding / withdrawing CAH).&#xD;
&#xD;
      It is, therefore, unsurprising that the provision of CAH at the end-of-life is extremely&#xD;
      variable within clinical practice (i.e. 12-88% cancer patients in the last week of life).&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      CAH during the last days of life reduces the frequency of hyperactive delirium (&quot;terminal&#xD;
      agitation&quot;) in cancer patients as a result of maintenance of renal perfusion and the&#xD;
      prevention of accumulation of toxins and drugs (i.e. prevention of dehydration).&#xD;
&#xD;
      Aims / objectives:&#xD;
&#xD;
      The aim of the definitive study is to evaluate the utility / role of CAH in cancer patients&#xD;
      in the last days of life.&#xD;
&#xD;
      The aim of the feasibility study is to answer the question &quot;can this study (the definitive&#xD;
      study) be done&quot;.&#xD;
&#xD;
      The objectives of the feasibility study are to:&#xD;
&#xD;
        -  assess the recruitment rate, i.e. number eligible patients, number recruited patients,&#xD;
           barriers to recruitment;&#xD;
&#xD;
        -  assess the retention rate;&#xD;
&#xD;
        -  assess impact of trial procedures on clinical workload, i.e. completion of clinical&#xD;
           assessment documentation, undertaking mouth care / CAH;&#xD;
&#xD;
        -  assess the adequacy of resources to conduct the study at research centres;&#xD;
&#xD;
        -  assess the adequacy of resources to support the study at Surrey Clinical Research&#xD;
           Centre;&#xD;
&#xD;
        -  determine other challenges for researchers / research centres;&#xD;
&#xD;
        -  determine other challenges for Surrey Clinical Research Centre;&#xD;
&#xD;
        -  assess safety of CAH&#xD;
&#xD;
        -  determine total variability / intra-cluster correlation coefficient&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
      The study is a cluster randomised trial with a mixed method of consenting. Consent sought&#xD;
      from patients (whenever possible), or advice from a &quot;personal consultee&quot; (when a patient is&#xD;
      unable to provide consent), or from a &quot;nominated consultee&quot; (when a patient is unable to&#xD;
      provide consent, and there is no personal consultee).&#xD;
&#xD;
      Sites will be randomised to either &quot;standard intervention arm A&quot;, or &quot;standard intervention&#xD;
      arm B&quot;. Patients in standard intervention arm A will be managed with continuance of oral&#xD;
      intake (if appropriate), and regular &quot;mouth care&quot;. Mouth care will be performed at least&#xD;
      every four hours, and will correspond to the investigational site's policy / procedures for&#xD;
      oral care in the terminal phase. Patients in standard intervention arm B will be managed with&#xD;
      continuance of oral intake (if appropriate), regular &quot;mouth care&quot;, and CAH, i.e. parenteral&#xD;
      fluids. Again, mouth care will be performed at least every four hours, and will correspond to&#xD;
      the investigational site's policy / procedures for oral care in the terminal phase. The&#xD;
      parenteral fluids may be administered either intravenously or subcutaneously at the&#xD;
      discretion of the medical and nursing team. The type of fluid to be administered will be&#xD;
      dextrose saline (i.e. 4% dextrose, 0.18% sodium chloride), and the volume to be administered&#xD;
      will be dependent on the patient's weight.&#xD;
&#xD;
      The primary endpoint of the definitive study is the frequency of hyperactive delirium&#xD;
      (&quot;terminal agitation&quot;), and this will be assessed using the Modified Richmond Agitation and&#xD;
      Sedation Scale (administered every four hours). Other data to be collected include the&#xD;
      frequency of pain, respiratory secretions / &quot;death rattle&quot;, dyspnoea, nausea and vomiting,&#xD;
      adverse effects from the CAH, and overall survival. In addition, data will be collected on&#xD;
      the use of anti-psychotic drugs, sedative drugs, analgesics, anti-secretory drugs, and other&#xD;
      end-of-life medication.&#xD;
&#xD;
      A &quot;cluster representation mechanism&quot; (CRM) will be utilised, including the appointment of&#xD;
      site-specific &quot;study guardians&quot; and &quot;study gatekeepers&quot;, who will protect and respect the&#xD;
      rights of the cluster and the individual participants within the cluster.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment rate</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Sample size is 200</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retention (% participants complete the study in a one year period)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>&gt; 67% participants complete the study in a one year period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence (% nursing observation completed in a one year period)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>&gt;67% nursing observation completed in a one year period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related adverse events</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>&lt;50% participants have clinically assisted hydration discontinued due to treatment- related adverse events, in a one year period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Non-Clinically Assisted Hydration arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The interventions utilised within this trial are representative of standard clinical practice&#xD;
Continuance of oral intake (if appropriate)&#xD;
Regular (4 hourly) mouth care&#xD;
Standard management of pain and other symptoms in the terminal phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinically Assisted Hydration arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The interventions utilised within this trial are representative of standard clinical practice&#xD;
Continuance of oral intake (if appropriate)&#xD;
Regular (4 hourly) mouth care&#xD;
Clinically-assisted hydration&#xD;
Standard management of pain and other symptoms in the terminal phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-Clinically Assisted Hydration arm</intervention_name>
    <description>Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care</description>
    <arm_group_label>Non-Clinically Assisted Hydration arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinically Assisted Hydration arm</intervention_name>
    <description>Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care, and clinically assisted hydration.</description>
    <arm_group_label>Clinically Assisted Hydration arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Diagnosis of cancer&#xD;
&#xD;
          -  Age ≥ 18 yr&#xD;
&#xD;
          -  Estimated prognosis of ≤ 1 week&#xD;
&#xD;
          -  Patient unable to maintain sufficient oral intake (1L / day)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patient clinically dehydrated&#xD;
&#xD;
          -  Patient has hyperactive delirium (&quot;terminal agitation&quot;) at present&#xD;
&#xD;
          -  Patient has had hyperactive delirium (&quot;terminal agitation&quot;) in the last 24hr&#xD;
&#xD;
          -  Clinical indication for clinically-assisted hydration (e.g. hypercalcaemia)&#xD;
&#xD;
          -  Clinical contra-indication to clinically-assisted hydration (e.g. cardiac failure)&#xD;
&#xD;
          -  Clinical contra-indication to peripheral cannulation&#xD;
&#xD;
          -  Intravenous fluids / subcutaneous fluids / total parenteral nutrition (TPN) / enteral&#xD;
             feeding or fluids already being administered&#xD;
&#xD;
          -  Patient likely to be transferred to another setting for end of life care (e.g. home,&#xD;
             hospice)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Davies</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Surrey County Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Clare Hospice</name>
      <address>
        <city>Harlow</city>
        <state>Essex</state>
        <zip>CM179JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leckampton Hall Hospice</name>
      <address>
        <city>Cheltenham</city>
        <state>Gloucestershire</state>
        <zip>GL53 0QJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pilgrims Hospice</name>
      <address>
        <city>Canterbury</city>
        <state>Kent</state>
        <zip>CT2 8JA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <state>Lancashire</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <state>Midlands</state>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Margaret's Hospice</name>
      <address>
        <city>Taunton</city>
        <state>Somerset</state>
        <zip>TA1 5HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Giles Hospice</name>
      <address>
        <city>Lichfield</city>
        <state>Staffordshire</state>
        <zip>WS14 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Surrey County Hospital NHS Foundation Trust</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Catherine's Hospice</name>
      <address>
        <city>Crawley</city>
        <state>Sussex</state>
        <zip>RH10 6BH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mary Hospice</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B29 7DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Richards Hospice</name>
      <address>
        <city>Worcester</city>
        <state>Worcestershire</state>
        <zip>WR5 2QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer centre</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>June 4, 2014</study_first_submitted>
  <study_first_submitted_qc>January 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>March 14, 2016</last_update_submitted>
  <last_update_submitted_qc>March 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>End-of-life care</keyword>
  <keyword>Clinically-assisted hydration</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

